The Food and Drug Administration (FDA) has approved gene therapy products for several conditions, such as cancer, spinal muscular atrophy, hemophilia, and sickle cell anemia. However, for most people, gene therapy is only available as part of a clinical trial. Below is a list of authorized products from the Office of Therapeutic Products (OTP). The Gene and Cell Therapy Institute (GCTI) at Mass General Brigham promotes medical innovation through two award programs that fund cutting-edge gene and cell therapy projects led by Mass.
General Brigham. Gene therapy involves replacing or modifying faulty genes with corrected versions, while cell therapy replaces or repairs damaged cells. With this “historic” approval in hand, there is a lot of optimism surrounding TIL therapy and cell therapy in general. The management of the Institute for Gene and Cell Therapy actively encourages and establishes internal and external connections to promote the advancement of gene and cell therapy treatments and innovative discoveries.
Many clinical trials with NK cells also employ combination therapies to maintain NK cell function directly or create synergies with therapy. To celebrate the achievements of the cell and gene therapy scientific community and patients, let's reflect on all cell and gene therapies approved by the FDA to date. Maus, doctor of medicine, associate director of the cell therapy and cell therapy program at the Institute of Gene and Cell Therapy, Paula O'Keeffe, director of the Mass General Cancer Center, of the Cellular Immunotherapy Program, professor of medicine at Massachusetts General Hospital, treating physician at Harvard Medical School, of the Hematopoietic Cell Transplant and Cell Therapy Program, MGH. The Gene and Cell Therapy Institute (GCTI) at Mass General Brigham is a center of innovation and collaboration that brings together more than 400 researchers and clinicians dedicated to the advancement of gene and cell therapy.
It should be noted that most stem cell therapy trials are in their early stages, with an almost equal representation in phase 1 (44%) and phase 2 (47%), demonstrating their considerable potential to influence the future reach of cell therapies. Cells, as living entities, have unique properties and are being harnessed as powerful therapies to treat diseases in a way that conventional therapies cannot. However, with its proven clinical success and continued clinical advances, cell therapy remains a very active area of research and it is expected that more innovative cell therapy products will emerge in the near future. Thanks to the Institute for Gene and Cell Therapy, Mass General Brigham's gene and cell therapy research is advancing rapidly, expanding the technological and clinical boundaries of this new frontier.
